These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15631353)

  • 1. Laminin, Her2/neu and Ki-67 as prognostic factors in non-small cell lung cancer.
    Szelachowska J; Jeleń M
    Rocz Akad Med Bialymst; 2004; 49():256-61. PubMed ID: 15631353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of intracellular laminin and Her2/neu overexpression in non-small cell lung cancer.
    Szelachowska J; Jelen M; Kornafel J
    Anticancer Res; 2006; 26(5B):3871-6. PubMed ID: 17094416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.
    Brabender J; Danenberg KD; Metzger R; Schneider PM; Park J; Salonga D; Hölscher AH; Danenberg PV
    Clin Cancer Res; 2001 Jul; 7(7):1850-5. PubMed ID: 11448895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
    Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
    Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T; Kinjo M; Nutahara K; Higashihara E
    Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers.
    Au NH; Cheang M; Huntsman DG; Yorida E; Coldman A; Elliott WM; Bebb G; Flint J; English J; Gilks CB; Grimes HL
    J Pathol; 2004 Sep; 204(1):101-9. PubMed ID: 15307143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.
    Iwasaki T; Nakagawa K; Nakamura H; Takada Y; Matsui K; Kawahara K
    Oncol Rep; 2005 Jun; 13(6):1075-80. PubMed ID: 15870924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
    Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
    Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
    Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
    Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
    Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology.
    Maddau C; Confortini M; Bisanzi S; Janni A; Montinaro F; Paci E; Pontenani G; Rulli P; Salani A; Zappa M; Benvenuti A; Carozzi FM
    Am J Clin Pathol; 2006 Mar; 125(3):425-31. PubMed ID: 16613347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer.
    Jung CK; Jung JH; Park GS; Lee A; Kang CS; Lee KY
    Pathol Int; 2006 Sep; 56(9):503-9. PubMed ID: 16930330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients.
    Wiesner FG; Magener A; Fasching PA; Wesse J; Bani MR; Rauh C; Jud S; Schrauder M; Loehberg CR; Beckmann MW; Hartmann A; Lux MP
    Breast; 2009 Apr; 18(2):135-41. PubMed ID: 19342238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
    Zhang Z; Ma J; Li N; Sun N; Wang C
    Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.